JP2018512175A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512175A5 JP2018512175A5 JP2018502608A JP2018502608A JP2018512175A5 JP 2018512175 A5 JP2018512175 A5 JP 2018512175A5 JP 2018502608 A JP2018502608 A JP 2018502608A JP 2018502608 A JP2018502608 A JP 2018502608A JP 2018512175 A5 JP2018512175 A5 JP 2018512175A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- glycosylated
- acid sequence
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021078780A JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562140135P | 2015-03-30 | 2015-03-30 | |
| US62/140,135 | 2015-03-30 | ||
| PCT/US2016/024691 WO2016160792A1 (en) | 2015-03-30 | 2016-03-29 | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078780A Division JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512175A JP2018512175A (ja) | 2018-05-17 |
| JP2018512175A5 true JP2018512175A5 (enExample) | 2019-05-09 |
| JP6936784B2 JP6936784B2 (ja) | 2021-09-22 |
Family
ID=57004606
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502608A Active JP6936784B2 (ja) | 2015-03-30 | 2016-03-29 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
| JP2021078780A Pending JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021078780A Pending JP2021129572A (ja) | 2015-03-30 | 2021-05-06 | グリコシル化ｐｄ−ｌ１に特異的な抗体およびその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10836827B2 (enExample) |
| EP (1) | EP3277320A4 (enExample) |
| JP (2) | JP6936784B2 (enExample) |
| KR (1) | KR102610592B1 (enExample) |
| CN (2) | CN114380909A (enExample) |
| WO (1) | WO2016160792A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| US9139653B1 (en) | 2015-04-30 | 2015-09-22 | Kymab Limited | Anti-human OX40L antibodies and methods of treatment |
| MA42971A (fr) | 2015-03-13 | 2018-08-15 | Cytomx Therapeutics Inc | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation |
| EP3277320A4 (en) | 2015-03-30 | 2018-08-01 | Stcube, Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| US11933786B2 (en) | 2015-03-30 | 2024-03-19 | Stcube, Inc. | Antibodies specific to glycosylated PD-L1 and methods of use thereof |
| CN109152798B (zh) * | 2015-12-02 | 2022-10-21 | 斯特库比股份有限公司 | 特异于糖基化的pd-1的抗体及其使用方法 |
| EP3436475A1 (en) | 2016-03-29 | 2019-02-06 | STCube & Co., Inc. | Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins |
| CN109195991B (zh) * | 2016-03-29 | 2023-10-31 | 斯特库比股份有限公司 | 对糖基化pd-l1特异的双重功能抗体及其使用方法 |
| WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
| US11746152B2 (en) | 2016-07-20 | 2023-09-05 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated PD-L1 |
| RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
| CN106478819B (zh) * | 2016-10-27 | 2018-12-07 | 常州费洛斯药业科技有限公司 | 一种针对pd-l1的单克隆抗体或抗体片段 |
| WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| CN106496327B (zh) * | 2016-11-18 | 2019-01-15 | 昆山百尔泰生物科技有限公司 | 针对pd-l1胞外段的人源抗体或抗体片段和用途、核苷酸序列和载体 |
| CN111051346A (zh) * | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
| CN110914302A (zh) | 2017-06-01 | 2020-03-24 | 赛托姆克斯治疗学股份有限公司 | 可活化抗pdl1抗体及其使用方法 |
| JP2020522562A (ja) | 2017-06-06 | 2020-07-30 | ストキューブ アンド シーオー．， インコーポレイテッド | Ｂｔｎ１ａ１又はｂｔｎ１ａ１リガンドに結合する抗体及び分子を用いて癌を治療する方法 |
| GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
| EP3694545A4 (en) | 2017-10-11 | 2021-12-01 | Board Of Regents, The University Of Texas System | HUMAN PD-L1 ANTIBODIES AND METHOD OF USING THEM |
| GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
| WO2019122882A1 (en) | 2017-12-19 | 2019-06-27 | Kymab Limited | Bispecific antibody for icos and pd-l1 |
| US12174193B2 (en) | 2018-01-15 | 2024-12-24 | Epiaxis Therapeutics Pty Ltd | Agents and methods for predicting response to therapy |
| FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
| US11976128B2 (en) | 2018-03-23 | 2024-05-07 | Board Of Regents, The University Of Texas System | Human PD-L2 antibodies and methods of use therefor |
| EP3768723A4 (en) | 2018-03-23 | 2021-12-29 | Board of Regents, The University of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| EP4501355A3 (en) * | 2018-03-23 | 2025-04-30 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor |
| WO2019195621A1 (en) * | 2018-04-04 | 2019-10-10 | Immutics, Inc. | Methods and compositions for blocking interaction between non-glycosylated pd-1 polypeptides |
| CN108315430B (zh) * | 2018-04-28 | 2021-07-23 | 上海交通大学医学院附属仁济医院 | Pdl1 snp基因型作为预测乳腺癌新辅助化疗疗效标记物的用途 |
| CN112351998B (zh) * | 2018-06-29 | 2022-07-22 | 苏州智核生物医药科技有限公司 | Pd-l1结合多肽及其用途 |
| CN110702916B (zh) * | 2019-04-15 | 2022-06-21 | 四川大学华西医院 | 一种整合蛋白质组和糖蛋白组的定量分析方法 |
| WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
| KR20220088428A (ko) | 2019-09-26 | 2022-06-27 | 주식회사 에스티큐브앤컴퍼니 | 글리코실화된 ctla-4에 대해 특이적인 항체 및 이의 사용 방법 |
| KR20220088438A (ko) | 2019-10-09 | 2022-06-27 | 주식회사 에스티큐브앤컴퍼니 | 글리코실화된 lag3에 대해 특이적인 항체 및 이의 사용 방법 |
| CN116234568A (zh) | 2020-07-07 | 2023-06-06 | 生物技术公司 | 用于hpv阳性癌症的治疗性rna |
| TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性ｒｎａ |
| WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
| WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
| IT202000031838A1 (it) * | 2020-12-22 | 2022-06-22 | Saverio Alberti | Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici |
| KR20230131236A (ko) * | 2021-01-06 | 2023-09-12 | 팔레온 파마슈티칼스 인크. | 항-pd-l1 항체 및 이의 융합 단백질 |
| TW202304506A (zh) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | 涉及抗claudin 18.2抗體的組合治療以治療癌症 |
| CA3219336A1 (en) | 2021-05-18 | 2022-11-24 | Kymab Limited | Uses of anti-icos antibodies |
| GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
| WO2023285552A1 (en) | 2021-07-13 | 2023-01-19 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
| MX2024001877A (es) | 2021-08-10 | 2024-02-28 | Kymab Ltd | Tratamiento de dermatitis atopica. |
| WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
| TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
| WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
| WO2023192976A1 (en) | 2022-04-01 | 2023-10-05 | Board Of Regents, The University Of Texas System | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor |
| EP4525991A1 (en) | 2022-05-18 | 2025-03-26 | Kymab Limited | Uses of anti-icos antibodies |
| CN120302979A (zh) | 2022-12-01 | 2025-07-11 | 生物技术公司 | 针对CD40和CD137的多特异性抗体与抗PD1 Ab和化学治疗的组合治疗 |
| JP2026501506A (ja) | 2022-12-14 | 2026-01-16 | アステラス・ファーマ・ヨーロッパ・ベスローデン・フェンノートシャップ | Ｃｌｄｎ１８．２及びｃｄ３に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法 |
| WO2024137442A1 (en) | 2022-12-21 | 2024-06-27 | Gilead Sciences, Inc. | Combination therapy for treating cancer |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| CN117756915B (zh) * | 2023-11-24 | 2025-05-30 | 河南省肿瘤医院 | 一组阻断抗pd-1抗体与细胞表面pd-1分子结合的pd-1分子及其突变体和用途 |
| WO2026033885A1 (en) | 2024-08-08 | 2026-02-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120866A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and agents stabilizing or increasing expression of cldn18.2 |
| WO2025120867A1 (en) | 2023-12-08 | 2025-06-12 | Astellas Pharma Inc. | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies |
| AR134560A1 (es) | 2023-12-08 | 2026-01-28 | Astellas Pharma Inc | Terapia de combinación que implica agentes de unión biespecíficos que se unen a cldn18.2 y cd3 y agentes que estabilizan o aumentan la expresión de cldn18.2 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030148406A1 (en) | 1992-03-17 | 2003-08-07 | David John King | Multivalent antigen-binding proteins |
| ES2367430T3 (es) * | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP1725585A2 (en) | 2004-03-10 | 2006-11-29 | Lonza Ltd | Method for producing antibodies |
| ES2427147T3 (es) | 2004-06-30 | 2013-10-29 | Mayo Foundation For Medical Education And Research | Anticuerpo sHlgM12 útil para tratar esclerosis múltiple |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| US20090011136A1 (en) * | 2005-05-06 | 2009-01-08 | Thomas Steven Lancsek | Composite electroless plating |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2007124361A2 (en) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | Soluble b7-h1 |
| US20080118978A1 (en) | 2006-04-28 | 2008-05-22 | Takashi Sato | Anti-tumor agent |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| WO2009089149A1 (en) * | 2008-01-03 | 2009-07-16 | The Johns Hopkins University | B7-h1 (cd274) antagonists induce apoptosis of tumor cells |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| MX356367B (es) * | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| EP2198884A1 (en) | 2008-12-18 | 2010-06-23 | Centre National de la Recherche Scientifique (CNRS) | Monoclonal antibodies directed against LG4-5 domain of alpha3 chain of human laminin-5 |
| EP3279215B1 (en) | 2009-11-24 | 2020-02-12 | MedImmune Limited | Targeted binding agents against b7-h1 |
| CA2791648A1 (en) * | 2010-03-01 | 2011-09-09 | The J. David Gladstone Institutes | Antibody specific for apolipoprotein and methods of use thereof |
| US9556281B2 (en) | 2011-08-15 | 2017-01-31 | The University Of Chicago | Compositions and methods related to antibodies to staphylococcal protein A |
| BR112014012819B1 (pt) * | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| BR112015007672A2 (pt) * | 2012-10-04 | 2017-08-08 | Dana Farber Cancer Inst Inc | anticorpos anti-pd-l1 monoclonais humanos e métodos de uso |
| EP2950814A4 (en) * | 2013-01-31 | 2016-06-08 | Univ Jefferson | FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| US10202454B2 (en) | 2013-10-25 | 2019-02-12 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| EP3277320A4 (en) | 2015-03-30 | 2018-08-01 | Stcube, Inc. | Antibodies specific to glycosylated pd-l1 and methods of use thereof |
| SI3356404T1 (sl) | 2015-10-02 | 2021-11-30 | F. Hoffmann-La Roche Ag | Protitelesa proti PD1 in postopki uporabe |
-
2016
- 2016-03-29 EP EP16773987.9A patent/EP3277320A4/en active Pending
- 2016-03-29 CN CN202111409317.7A patent/CN114380909A/zh active Pending
- 2016-03-29 KR KR1020177031205A patent/KR102610592B1/ko active Active
- 2016-03-29 WO PCT/US2016/024691 patent/WO2016160792A1/en not_active Ceased
- 2016-03-29 CN CN201680026424.2A patent/CN107530429B/zh active Active
- 2016-03-29 JP JP2018502608A patent/JP6936784B2/ja active Active
- 2016-03-29 US US15/559,513 patent/US10836827B2/en active Active
-
2021
- 2021-05-06 JP JP2021078780A patent/JP2021129572A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7335290B2 (ja) | 二重特異性四価抗体並びにその製作及び使用方法 | |
| US10669339B2 (en) | Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof | |
| US20160280798A1 (en) | Alk antibodies, conjugates, and chimeric antigen receptors, and their use | |
| JP2022513053A (ja) | Ｂ７－Ｈ３のＩｇＶドメインに対するモノクローナル抗体及びその使用 | |
| CN108368170A (zh) | 抗pd-1抗体、可活化抗pd-1抗体及其使用方法 | |
| TW201643195A (zh) | 對細胞內致癌基因產物的單株抗原結合蛋白 | |
| JP6603227B2 (ja) | Ｐ９７融合タンパク質 | |
| US9676846B2 (en) | Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II | |
| JP2025508118A (ja) | 新規免疫調節剤の開発および使用 | |
| US20220056146A1 (en) | Antibodies and Antigen Binding Fragments Against CD155 Methods of Use Thereof | |
| CA2959671C (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
| KR20170064545A (ko) | L1cam에 결합하는 신규한 결합 분자 특히 항체(cd171) | |
| CN114786720B (zh) | TriAx抗体的组合物及其制备和使用方法 | |
| CA3229327A1 (en) | Antibodies and antigen binding fragments against cd155 methods of use thereof | |
| CN120435306A (zh) | 嵌合抗原受体t细胞的可逆控制 | |
| US9499622B2 (en) | Anti-EGFR/anti-HER2 bispecific antibodies with anti-EGFR DARPins | |
| WO2023221935A1 (zh) | 结合pd-l1和cldn18.2的抗体及其用途 | |
| CN121079324A (zh) | 抗cntn4抗体及其用途 | |
| JP2022504472A (ja) | Ｈｅｒ２結合四量体ポリペプチド | |
| CN119816519A (zh) | 抗ror1抗体、包含其的双特异性抗体及其用途 | |
| CN119233995A (zh) | 治疗实体瘤的方法 | |
| CN118108842A (zh) | 人源化抗cd24抗体及其应用 | |
| JP7080896B2 (ja) | 抗ｄｒ５抗体およびその用途 | |
| WO2025117872A1 (en) | Bispecific antibody-like protein and methods of making and using thereof | |
| US20220002435A1 (en) | Antibodies targeting epn1 |